Categories: Research

Studies of improved over-the-counter acetaminophen warning labels, more accurate measurements of antibiotics in hospitalized patients, therapies for metastatic breast cancer, and methods for training pharmacy personnel to help smokers quit took top honors at the Department of Clinical Pharmacy’s...

For the 34th consecutive year, the UCSF School of Pharmacy has received more research funding from the National Institutes of Health (NIH) than any other pharmacy school in the United States.

School researchers were awarded $29.2 million during the 2013 NIH fiscal year, from October 1, 2012 to...

A new analysis of dozens of animal studies evaluating the effects of the cholesterol-lowering statin class of drugs on atherosclerosis found larger positive effects in studies not sponsored by the pharmaceutical industry as compared to those that were industry sponsored.

Studies of whether patients are taking a blood thinner as prescribed, whether antibiotic treatment of cancer patients’ fevers matches guidelines, and whether one form of a leading cardiovascular drug increases the risk for a serious side effect took top honors at the Department of Clinical Pharmacy...

Improving technologies are rapidly cutting the cost of whole genome sequencing, a process that reveals the complete library of a patient’s genetic information. Indeed, the era of the $1,000 genome—a catchphrase for the test’s relative affordability—appears imminent.

How well do states’ policies address possible conflicts of interest of committee members who decide which drugs get Medicaid reimbursement? The question looms especially large as impending federal health care reform increases the number of patients covered by the state-run drug formularies.

An updated and expanded review of clinical research papers on drugs and medical devices finds that industry-sponsored studies are more likely to lead to favorable results, including reports of greater benefits and fewer harmful side effects.

Systematic reviews seek to answer key questions about the relative effectiveness and safety of medical interventions by selecting, combining, and critically evaluating the research in published medical literature.

Health policy expert Lisa Bero, PhD, is hailed in the latest issue of The Lancet for tackling hot-button subjects such as financial biases in drug research.

Studies of cancer drug dosing in children, possible medication links to delirium in hospital patients, and how to decide when swallowed batteries may call for invasive removal took top honors at the Department of Clinical Pharmacy’s 14th annual Spring Research Seminar.